Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc.
- Market cap
- $3.25K
Your view on JSPRW
Overview
What the company does, where it operates, and who runs it.
About Jasper Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeet Mahal
- Headquarters
- 2200 Bridge Pkwy, Redwood City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeet Mahal
- Headquarters
- 2200 Bridge Pkwy, Redwood City, CA, US
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Jasper Therapeutics, Inc.. Starting points for Jasper Therapeutics, Inc.: EPS -$0.01, beta 3.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Jasper Therapeutics, Inc.. Trailing twelve-month EPS for Jasper Therapeutics, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
1 rating- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.44 | −$0.03 | −$0.67 | −$0.73 |
| Lowest estimate | −$0.44 | −$0.03 | −$0.67 | −$0.73 |
| Highest estimate | −$0.44 | −$0.03 | −$0.67 | −$0.73 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | −$0.321 | −$0.041 | −$118.501 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $8.00M | $8.00M | $12.00M | $173800.00 |
| Lowest estimate | $8.00M | $8.00M | $12.00M | $173800.00 |
| Highest estimate | $8.00M | $8.00M | $12.00M | $173800.00 |
| Number of analysts | 4 | 4 | 5 | 2 |
| A year ago | $0.00 | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Jasper Therapeutics, Inc.. Jasper Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AZTRAzitra, Inc. | Healthcare | Biotechnology | $3.1M | ||
| ENVBEnveric Biosciences, Inc. | Healthcare | Biotechnology | $6.0M | ||
| INDPIndaptus Therapeutics, Inc. | Healthcare | Biotechnology | $319.3M | ||
| ONCOOnconetix, Inc. | Healthcare | Biotechnology | $1.0M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | Biotechnology | $470,654 | ||
| REVBRevelation Biosciences, Inc. | Healthcare | Biotechnology | $2.0M | ||
| SCNIScinai Immunotherapeutics Ltd. | Healthcare | Biotechnology | $204,191 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BCTXBriaCell Therapeutics Corp. | Healthcare | NASDAQ | $26.7M | ||
| BCTXZBriaCell Therapeutics Corp. Warrant | Healthcare | NASDAQ | $243,944 | ||
| BCYCBicycle Therapeutics plc | Healthcare | NASDAQ | $203.3M | ||
| BDRXBiodexa Pharmaceuticals Plc | Healthcare | NASDAQ | $174,870 | ||
| BDTXBlack Diamond Therapeutics, Inc. | Healthcare | NASDAQ | $75.3M | ||
| BEAMBeam Therapeutics Inc. | Healthcare | NASDAQ | $2.2B | ||
| BETR.CNBetterLife Pharma Inc. | Healthcare | CNQ | — | ||
| BETRFBetterLife Pharma Inc. | Healthcare | OTC | $6.4M | ||
| BHVNBiohaven Ltd. | Healthcare | NYSE | $1.9B | ||
| BICTFBiocure Technology Inc. | Healthcare | OTC | $379,088 | ||
| BIOABioAge Labs, Inc. | Healthcare | NASDAQ | $161.1M | ||
| BIOAFBioasis Technologies Inc. | Healthcare | OTC | $15,883 | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Jasper Therapeutics, Inc. executives and directors. Shares of Jasper Therapeutics, Inc. have traded between $0.0092 and $0.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Jasper Therapeutics, Inc.. Coverage tracks Jasper Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Jasper Therapeutics, Inc.